Iguratimod is an emerging disease‐modifying antirheumatic drug (DMARD) that has attracted attention due to its dual ability to control inflammatory pathways and provide bone protection in rheumatoid ...
Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results